Keywords: XOMA, Servier, XOMA-052, Anti-inflammatory

XOMA and Lab Servier in deal for multi-indication drug candidate worth a potential $505 million

Article | 05 January 2011

Print This

Shares of US firm XOMA (Nasdaq: XOMA) leapt 38% to $7.31 by close of trading yesterday after it announced the signing of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in